SECTION 1. IDENTIFICATION

Product name : Peginterferon Alfa-2b Powder Formulation
Other means of identification : No data available

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

Reproductive toxicity : Category 1B

GHS label elements
Hazard pictograms :

Signal Word : Danger
Hazard Statements : H360FD May damage fertility. May damage the unborn child.
Precautionary Statements :

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sucrose .alpha.-D-Glucopyranoside,.beta.-D-fructofuranosyl</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>No data available</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Thoroughly clean clothing before reuse.
Wash clothing before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage fertility. May damage the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>09/26/2023</td>
<td>20512-00025</td>
<td>03/20/2023</td>
<td>10/09/2014</td>
</tr>
</tbody>
</table>

Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Metal oxides
Phosphorus compounds
Oxides of phosphorus
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust.
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
- Strong oxidizing agents
- Self-reactive substances and mixtures
- Organic peroxides
- Explosives
- Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA EV</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>215647-85-1</td>
<td>TWA (inhalable fraction)</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are...
designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Personal protective equipment**

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type: Particulates type
- Material: Chemical-resistant gloves

**Hand protection**
- Remarks: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection**
- Wear the following personal protective equipment:
  - Safety goggles

**Skin and body protection**
- Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
- Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Appearance</strong></td>
<td>powder</td>
</tr>
<tr>
<td><strong>Color</strong></td>
<td>White to light yellow</td>
</tr>
<tr>
<td><strong>Odor</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Odor Threshold</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>pH</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Melting point/freezing point</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Initial boiling point and boiling range</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Flash point</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Evaporation rate</strong></td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Density : 1 g/cm³
Solubility(ies) Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity Viscosity, dynamic : No data available
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
**SAFETY DATA SHEET**

according to the Hazardous Products Regulations

**Peginterferon Alfa-2b Powder Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>09/26/2023</td>
<td>20512-00025</td>
<td>03/20/2023</td>
<td>10/09/2014</td>
</tr>
</tbody>
</table>

Hazardous decomposition products: No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

**Information on likely routes of exposure**

**Inhalation**

**Skin contact**

**Ingestion**

**Eye contact**

**Acute toxicity**

Not classified based on available information.

**Components:**

**Sucrose:**

Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

**Peginterferon Alfa-2b:**

Acute toxicity (other routes of administration): LD50 (Rat): > 20.1 mg/kg

Application Route: Intravenous

LD50 (Monkey): > 9.8 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Peginterferon Alfa-2b:**

Species: Rabbit

Result: Mild skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:**

**Peginterferon Alfa-2b:**

Species: Rabbit

Result: Mild eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.
Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Peginterferon Alfa-2b:
Genotoxicity in vitro: Test Type: reverse mutation assay
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative
Genotoxicity in vivo: Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Peginterferon Alfa-2b:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Monkey, female
Application Route: Subcutaneous
Dose: 0.35 milligram per kilogram
Symptoms: Effect on estrous cycle
Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments,
Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Components:

Peginterferon Alfa-2b:
Target Organs: Gastrointestinal tract, Immune system, Cardio-vascular system, Endocrine system, Central nervous system, Liver, Respiratory Tract, Eye
Assessment: Causes damage to organs through prolonged or repeated
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

Repeated dose toxicity

Components:

Peginterferon Alfa-2b:
Species: Mouse
NOAEL: 0.0038 mg/kg
Application Route: Subcutaneous
Exposure time: 9 d

Species: Rat
NOAEL: 0.0042 mg/kg
Application Route: Subcutaneous
Exposure time: 30 d

Species: Monkey
LOAEL: 0.12 mg/kg
Application Route: Subcutaneous
Exposure time: 30 d
Target Organs: Blood, Bone marrow, Immune system

Species: Monkey
NOAEL: 0.015 mg/kg
LOAEL: 0.077 mg/kg
Exposure time: 3 Months
Target Organs: Respiratory Tract, Cardio-vascular system, Central nervous system, Bone marrow

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Peginterferon Alfa-2b:
Inhalation: Symptoms: flu-like symptoms, Gastrointestinal disturbance, mental depression, tingling

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Peginterferon Alfa-2b:
Ecotoxicology Assessment
Acute aquatic toxicity: No data available
Chronic aquatic toxicity: No data available
Persistence and degradability

Components:

Peginterferon Alfa-2b:

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
TDG
Not regulated as a dangerous good
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

Version 4.1  
Revision Date: 09/26/2023  
SDS Number: 20512-00025  
Date of last issue: 03/20/2023  
Date of first issue: 10/09/2014

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Report Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>USA. ACGIH Threshold Limit Values (TLV)</td>
</tr>
<tr>
<td>CA AB OEL</td>
<td>Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)</td>
</tr>
<tr>
<td>CA BC OEL</td>
<td>Canada. British Columbia OEL</td>
</tr>
<tr>
<td>CA QC OEL</td>
<td>Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants</td>
</tr>
<tr>
<td>ACGIH / TWA</td>
<td>8-hour, time-weighted average</td>
</tr>
<tr>
<td>CA AB OEL / TWA</td>
<td>8-hour Occupational exposure limit</td>
</tr>
<tr>
<td>CA BC OEL / TWA</td>
<td>8-hour time weighted average</td>
</tr>
<tr>
<td>CA QC OEL / TWAEV</td>
<td>Time-weighted average exposure value</td>
</tr>
</tbody>
</table>

Abbreviations:

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Peginterferon Alfa-2b Powder Formulation

Version  Revision Date:  SDS Number:  Date of last issue:  Date of first issue:
4.1     09/26/2023    20512-00025    03/20/2023    10/09/2014

1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System


Revision Date: 09/26/2023
Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8